Please wait a minute...
European Journal of Gynaecological Oncology  2020, Vol. 41 Issue (5): 774-778    DOI: 10.31083/j.ejgo.2020.05.5044
Original Research Previous articles | Next articles
MiR-29 promotes ovarian carcinoma cell proliferation through the PTEN pathway
Qianqian Tang1, Shi Wan1, Xiaogai Qiao1, Fang Wang1, Yan Wang1, *()
1Department of gynecology and obstetrics, Second Affiliated Hospital of Zhengzhou University, Zhengzhou, 450014, P. R. China
Download:  PDF(1429KB)  ( 100 ) Full text   ( 6 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
The objective of this study was to investigate the role of miR-29 in ovarian carcinoma progression. Cell proliferation was measured with a cell counter. mRNA expression of miR-29, phosphatase and tensin homolog (PTEN), and proliferating cell nuclear antigen (PCNA) was measured by RT-PCR. Protein expression was detected by Western blot. The results demonstrated that miR-29 expression was upregulated in ovarian carcinoma and that miR-29 promoted cell proliferation. Consistently, miR-29 silencing decreased ovarian carcinoma cell proliferation. Mechanistically, we found PTEN expression was decreased following miR-29 overexpression and PTEN expression was increased following miR-29 silencing. Importantly, overexpression of PTEN was sufficient to inhibit ovarian carcinoma cell proliferation, demonstrating a key role for PTEN downstream of miR-29. Therefore, our study highlights the miR-29-PTEN pathway as a critical mediator of ovarian cancer cell proliferation, providing a new therapeutic target for patients with ovarian carcinoma.
Key words:  Ovarian carcinoma      MiR-29      PTEN      Cell proliMferation     
Submitted:  07 October 2018      Accepted:  07 January 2019      Published:  15 October 2020     
*Corresponding Author(s):  YAN WANG     E-mail:  flowertree2020@126.com

Cite this article: 

Qianqian Tang, Shi Wan, Xiaogai Qiao, Fang Wang, Yan Wang. MiR-29 promotes ovarian carcinoma cell proliferation through the PTEN pathway. European Journal of Gynaecological Oncology, 2020, 41(5): 774-778.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2020.05.5044     OR     https://ejgo.imrpress.com/EN/Y2020/V41/I5/774

[1] Yuqing Yang, Huimin Zhang, Weiming Chen, Xiaoyue Chen, Xiaolin Yu. Lapatinib promotes ovarian cancer cell apoptosis through mROS-HtrA2/Omi pathways[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 598-603.
[2] H. Ishibashi, M. Miyamoto, T. Aoyama, H. Soyama, H. Matsuura, H. Iwahashi, M. Takano, K. Furuya. The effect of six scheduled cycles of neoadjuvant chemotherapy on prognosis in advanced ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 386-390.
[3] Q. Huang, Y. He, X. Cao, C. Yi. PTEN and CD146 expression in endometrioid adenocarcinoma[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 439-443.
[4] S. Kalogeropoulos, E. Chronopoulou, E. Kourea, A. Siampalis, A. Kaponis, G. O Decavalas. Small cell ovarian carcinoma hypercalcemic type and endometrial adenocarcinoma in a 49-year-old patient: a very rare case[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 1064-1066.
[5] S. Cierniak, R. Koktysz, M. Jesiotr, A. Gąsowska-Bodnar, L. Bodnar. Expression of the PI3K/AKT/mTOR pathway as a prognostic factor in patients with advanced high grade serous ovarian carcinoma treated with neoadjuvant chemotherapy[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 744-751.
[6] L.A. Karakas, Y.A. Tohma, E. Kuscu, O. Ozen, A. Ayhan. Analysis of Bcl-2, PTEN, p53, and Ki-67 expressions in endometrial cancer arising from endometrial polyp[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 796-802.
[7] Yi Lin, Qiong Duan, Youping Yang, Yangli Zhu, Jie Zhang, Chunge Dong. Immunohistochemistry of phosphatase and tensin homolog and metalloproteinase-9 in breast invasive micropapillary carcinoma[J]. European Journal of Gynaecological Oncology, 2019, 40(3): 380-383.
[8] Lan Zhong, Feng Deng, Xingsheng Shu, Zhilan Peng. P53 overexpression predicts unfavorable prognosis of low risk endometrial carcinoma[J]. European Journal of Gynaecological Oncology, 2019, 40(3): 463-467.
[9] C.E.S. Hoogstins, L.S.F. Boogerd, K.N. Gaarenstroom, C.D. de Kroon, J.J. Beltman, J.B.M.Z. Trimbos, T. Bosse, J. Vuyk, P.S. Low, J. Burggraaf, A.L. Vahrmeijer. Feasibility of folate receptor-targeted intraoperative fluorescence imaging during staging procedures for early ovarian cancer[J]. European Journal of Gynaecological Oncology, 2019, 40(2): 203-208.
[10] Xin Yan, Yu-Nong Gao, Quan Bao, Na An, Min Gao, Hong Zheng. Hepatic resection for recurrent metastatic ovarian carcinoma or peritoneal carcinoma: a retrospective case-control study[J]. European Journal of Gynaecological Oncology, 2019, 40(1): 113-118.
[11] Ka Yu Tse, Philip Pun Ching Ip, Suk Kwan Lau, Tong Yow Ng, Kar Fai Tam, Annie Nga Yin Cheung, Hextan Yuen Sheung Ngan. Poor prognosis associated with venous thromboembolism in Asian patients with ovarian clear cell carcinoma[J]. European Journal of Gynaecological Oncology, 2018, 39(6): 903-910.
[12] F. Lai-Tiong. Long survival metastatic ovarian neoplasm under bevacizumab maintenance strategy[J]. European Journal of Gynaecological Oncology, 2018, 39(6): 1015-1016.
[13] S. Pantovic, A. Stefanovic, J. Dotlic, S. Kadija, K. Jeremic, I. Likic, S. Repac, J. Stojnic, Z. Vilendecic, I. Pilic. Ovarian carcinoma diagnostic challenge: large ovarian carcinoma giving umbilical subcutaneous metastases without infiltrating intestines[J]. European Journal of Gynaecological Oncology, 2018, 39(5): 813-816.
[14] Ling Wang, Xiao-tong Wu, Bo-wei Wang, Qiang Wang, Li-ying Han. miR-145 regulates proliferation and chemotherapy sensitivity of ovarian carcinoma[J]. European Journal of Gynaecological Oncology, 2018, 39(4): 634-640.
[15] W. MacNab, R.M. Glasspool, S. Shanbhag, A.H. Sadozye, K.A. Burton, I.A. McNeish, N.S. Reed, N. Siddiqui, M.K. Mehasseb. Outcomes of women not receiving treatment for advanced ovarian cancer in the West of Scotland: a retrospective analysis[J]. European Journal of Gynaecological Oncology, 2018, 39(1): 58-62.
[1] Eli M. Roth, Michael H. Davidson. PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety[J]. Reviews in Cardiovascular Medicine, 2018, 19(S1): 31 -46 .
[2] B. Soltész, J. Lukács, A. Penyige, R. Póka, B. Nagy. Determination of miR-193b rs30236 single nucleotide polymorphism in ovarian cancer patients[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 547 -550 .
[3] Y. Li, C. Li, N. Li, L. Jiang, W. Yang, Y. Wang, B. Wu, C. Shi, Z. Zhu. RNAi silenced NUP88 gene suppresses growth and invasiveness of human breast cancer cell line MCF-7[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 634 -639 .
[4] M. Pakiž, L. Lukman, N. Kozar. Patients' and physicians' expectations differ significantly during the follow-up period after completion of primary treatment of gynecological or breast cancer[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 781 -786 .
[5] T. Tomimatsu, S. Mabuchi, T. Tsuboyama, Y. Hori, S. Sekine, T. Kimura. Malignant transformation of uterine leiomyoma: suggested by clinical, imaging, histological, and genetic findings[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 879 -882 .
[6] Z. Protrka, P. Arsenijevic, N. Jovic, S. Zivanovic, J. Djuric, A. Dimitrijevic. A case of uterine torsion in term pregnancy associated with placental abruption and intrauterine fetal demise[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(2): 287 -289 .
[7] T. Ueno, H. Yabushita, K. Iwasaki, A. Wakatsuki. Role of adiponectin and leptin in non-diabetic, non-obese patients with endometrial cancer[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 199 -204 .
[8] P. Pimsi, W. Santimaleeworagun, S. Therasakvichya, N. Saengsukkasemsak, A. Laocharoenkeat. The incidence and risk factors of severe neutropenia and febrile neutropenia due to chemotherapy among gynecologic cancer patients in Thailand[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 242 -246 .
[9] F. Lai-Tiong. Dermatomyositis revealing a 18-year breast cancer recurrence[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 292 -293 .
[10] M.F. Benoit, K.A. O'Hanlan, M.S. Sten, C.L. Kosnik, D.M. Struck, M.S. O'Holleran, J. Cuff, D.M. Halliday, E.A. Kent. Incidental appendectomy at the time of gynecologic surgery[J]. European Journal of Gynaecological Oncology, 2018, 39(3): 386 -389 .